[go: up one dir, main page]

CN117517656B - Lp-PLA2 antigen preservation solution - Google Patents

Lp-PLA2 antigen preservation solution Download PDF

Info

Publication number
CN117517656B
CN117517656B CN202311215216.5A CN202311215216A CN117517656B CN 117517656 B CN117517656 B CN 117517656B CN 202311215216 A CN202311215216 A CN 202311215216A CN 117517656 B CN117517656 B CN 117517656B
Authority
CN
China
Prior art keywords
phosphate
buffer
pla2
surfactant
pla2 antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202311215216.5A
Other languages
Chinese (zh)
Other versions
CN117517656A (en
Inventor
张宁
陈小茹
吴向东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Amtech Bioengineering Ltd inc
Original Assignee
Shenzhen Amtech Bioengineering Ltd inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Amtech Bioengineering Ltd inc filed Critical Shenzhen Amtech Bioengineering Ltd inc
Priority to CN202311215216.5A priority Critical patent/CN117517656B/en
Publication of CN117517656A publication Critical patent/CN117517656A/en
Application granted granted Critical
Publication of CN117517656B publication Critical patent/CN117517656B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N2001/2893—Preparing calibration standards
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention discloses a composition comprising a buffer, an inorganic salt, a phosphate surfactant, a nonionic surfactant, a stabilizer and a preservative. The Lp-PLA2 antigen preservation solution can keep the prepared liquid Lp-PLA2 calibrator or quality control product stable, does not influence the detection accuracy and repeatability, can prolong the storage period, and does not need freeze-drying.

Description

Lp-PLA2 antigen preservation solution
Technical Field
The invention relates to the field of biochemistry, in particular to an Lp-PLA2 antigen preservation solution.
Background
Lipoprotein-associated phospholipase A2 (Lipoprotein-associatedphospholipase A2, lp-PLA 2) is encoded by the PLA2G7 gene, also known as platelet-activating factor acetylhydrolase (PLATELET ACTIVATING factor-AH, PAF-AH), a subclass belonging to the phospholipase A2 superfamily, and is a non-calcium ion dependent protein consisting of 441 amino acids with a relative molecular mass of 45.4 kD. Lp-PLA2 catalyzes the hydrolysis of the glycerophospholipid-two-position acyl ester bonds on lipoproteins and cell membranes to produce oxidized free fatty acids (NEFA) and Lysophosphatidylcholine (LPC). Human plasma Lp-PLA2 is synthesized and secreted primarily by mature macrophages, T lymphocytes, monocytes and mast cells, all of which play a critical role in the formation of atherosclerosis. Lp-PLA2 exists in plasma in a form of binding to lipoprotein particles, of which 80% is bound to Low Density Lipoprotein (LDL) by apolipoprotein B (ApoB) and the remaining 20% is bound to High Density Lipoprotein (HDL) and Very Low Density Lipoprotein (VLDL) by other apolipoproteins. Lp-PLA2 is involved in various stages of atherosclerotic plaque formation and is an independent risk factor for arteriosclerotic cardiovascular disease.
The kit for detecting the Lp-PLA2 on the market has a plurality of methodologies, and has two mass methods and an enzyme method, and a stable Lp-PLA2 calibrator and a stable quality control product are required to be matched. The natural Lp-PLA2 has low content in blood, is usually combined with lipoprotein, can be used as a raw material of a calibrator and a quality control product, and can be blocked by a recognition site of a combined antibody in a kit, while the recombinant Lp-PLA2 protein needs to be frozen for preservation, and is difficult to be stable for a long time at 2-8 ℃ in a specific preservation solution because of not being combined with the lipoprotein. In order to solve the problems, the calibration product and the quality control product are freeze-dried, and are only required to be re-dissolved before use and are stable for one week at 2-8 ℃. However, the calibrator concentration may change after reconstitution after lyophilization and there is a risk of batch-to-batch and bottle-to-bottle differences. Therefore, there is a great clinical need for liquid stable Lp-PLA2 calibrators and quality controls.
Disclosure of Invention
The invention provides an Lp-PLA2 antigen preservation solution and application thereof, and aims to solve the technical problem that the existing liquid calibrator and quality control product are difficult to keep stable for a long time.
The invention provides an Lp-PLA2 antigen preservation solution, which comprises a buffering agent, inorganic salt, phosphate surfactant, nonionic surfactant, stabilizer and preservative.
Further, the buffer agent comprises 10-200mM, 5-20g/L of inorganic salt, 0.01-5g/L of phosphate surfactant, 0.1-10g/L of nonionic surfactant, 0.5-100g/L of stabilizer and 0.5-2g/L of preservative.
Further, the buffer is any one of phosphate buffer, tris-HCl buffer, good's buffer, citrate buffer, barbital buffer and borate buffer, the pH of the buffer is 6.0-8.5, and the concentration of the buffer is 10-200mM.
Further, the inorganic salt is any one of sodium chloride, potassium chloride, magnesium chloride, sodium sulfate and magnesium sulfate, and the concentration of the inorganic salt is 5-20g/L.
Further, the phosphate surfactant is composed of a hydrophilic part and a hydrophobic part, wherein the hydrophobic part is alkyl or fatty acid, and the hydrophilic part is phosphate.
Further, the phosphate surfactant is one or salts of alkyl phosphate, aryl phosphate, fatty alcohol polyoxyethylene ether phosphate, alkylphenol polyoxyethylene ether phosphate, alkyl alcohol amide phosphate, imidazoline phosphate and high polymer polyphosphate.
Further, the phosphate surfactant has the structure thatThe R 1、R2 and R 3 are the same or different hydrophobic groups.
Further, the concentration of the phosphate surfactant is 0.01-5g/L.
Further, the nonionic surfactant is one or more of polyol polyoxyethylene ether fatty acid ester, alkylphenol polyoxyethylene ether, octyl phenyl polyoxyethylene ether and polysorbate, the hydrophilic-lipophilic balance value of the nonionic surfactant is 13-18, and the concentration of the nonionic surfactant is 0.1-10g/L.
Further, the stabilizer is any one or more of polyalcohol, sugar, macromolecular inert protein and high molecular polymer, wherein the polyalcohol is glycol, glycerol, mannitol, sorbitol, sucrose, trehalose or chitosan, the macromolecular inert protein is bovine serum albumin, human serum albumin, casein or gelatin, the high molecular polymer is polyvinylpyrrolidone, and the concentration of the stabilizer is 0.5-100g/L.
Further, the preservative is any one or more of sodium azide, proClin, gentamicin, nipagin esters and isothiazolinones, and the concentration of the preservative is 0.5-2g/L.
The invention also provides an application of the Lp-PLA2 antigen preservation solution in preparing stable liquid Lp-PLA2 calibrator and quality control product.
Compared with the prior art, the invention has the beneficial effects that:
(1) The Lp-PLA2 antigen preservation solution can keep the prepared liquid Lp-PLA2 calibrator or quality control product stable, does not influence the detection accuracy and repeatability, can prolong the storage period, and does not need freeze-drying.
(2) The invention has the advantages of simple preparation, easily obtained raw materials, low cost, no toxicity and biological safety risk.
Detailed Description
In order to make the technical problems, technical schemes and beneficial effects to be solved more clear, the invention is further described in detail below with reference to the embodiments. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention. The present invention will be specifically described with reference to the following specific examples.
The embodiment of the invention provides an Lp-PLA2 antigen preservation solution, which comprises a buffer agent, inorganic salt, phosphate surfactant, nonionic surfactant, stabilizer and preservative.
Wherein the buffer provides a stable pH range; the inorganic salt provides salt ions, and the salt ions with a certain concentration can promote the dissolution of protein in water; the alpha helix of the natural Lp-PLA2 is easy to combine with the phospholipid monolayer part of HDL or LDL to be stable, but the recombinant Lp-PLA2 lacking lipoprotein is not easy to be stable, and the addition of the phosphate surfactant is equivalent to the blocking of the lipoprotein combining part, and simultaneously the spatial structure of the Lp-PLA2 is protected; nonionic surfactants can reduce hydrophobic collisions between proteins to stabilize; stabilizers such as saccharides, inert proteins, polyols and the like can promote protein dissolution, prevent protein surface from losing water, and maintain protein space conformation stable; the preservative can prevent the protein from being degraded by bacteria. The buffering agent, inorganic salt, stabilizer and preservative in the materials are basic formulas for stabilizing most proteins, but according to the molecular structure of Lp-PLA2, the addition of phosphate surfactants is the most critical, and the addition of nonionic surfactants can promote the dissolution of phosphate surfactants, so that the Lp-PLA2 and lipoprotein binding sites can be better blocked, the protein space structure is not damaged, and the stabilizing effect is achieved.
Specifically, the buffer agent comprises 10-200mM, 5-20g/L of inorganic salt, 0.01-5g/L of phosphate surfactant, 0.1-10g/L of nonionic surfactant, 0.5-100g/L of stabilizer and 0.5-2g/L of preservative.
Specifically, the buffer is any one of phosphate buffer, tris-HCl buffer, good's buffer, citrate buffer, barbital buffer, borate buffer and the like, the pH of the buffer is 6.0-8.5, and the concentration of the buffer is 10-200mM.
Specifically, the inorganic salt is any one of sodium chloride, potassium chloride, magnesium chloride, sodium sulfate, magnesium sulfate and the like, and the concentration of the inorganic salt is 5-20g/L.
Specifically, the phosphate surfactant consists of a hydrophilic part and a hydrophobic part, wherein the hydrophobic part is alkyl or fatty acid, and the hydrophilic part is phosphate.
Specifically, the phosphate surfactant is alkyl (aryl) phosphate, fatty alcohol (alkylphenol) polyoxyethylene ether phosphate, alkyl alcohol amide phosphate, imidazoline phosphate, polymer polyphosphate, etc., and exists in the form of salt to promote water solubility.
Specifically, the phosphate surfactant has the structure thatThe R 1、R2 and R 3 are the same or different hydrophobic groups.
Specifically, the concentration of the phosphate surfactant is 0.01-5g/L.
Specifically, the nonionic surfactant is one or more of polyol polyoxyethylene ether fatty acid ester, alkylphenol polyoxyethylene ether, octylphenyl polyoxyethylene ether, polysorbate and the like, the hydrophilic-lipophilic balance (HLB) of the nonionic surfactant is 13-18, and the concentration of the nonionic surfactant is 0.1-10g/L.
Specifically, the stabilizer is any one or more of polyalcohol, saccharide, macromolecular inert protein and high molecular polymer.
Specifically, the polyalcohol is glycol, glycerol, mannitol, sorbitol, sucrose, trehalose, chitosan or the like, the macromolecular inert protein is bovine serum albumin, human serum albumin, casein, gelatin or the like, the high polymer is polyvinylpyrrolidone, and the concentration of the stabilizer is 0.5-100g/L.
Specifically, the preservative is any one or more of sodium azide, proClin, gentamicin, nipagin esters, isothiazolinones and the like, and the concentration of the preservative is 0.5-2g/L.
The embodiment of the invention also provides an application of the Lp-PLA2 antigen preservation solution in preparing stable liquid Lp-PLA2 calibrator and quality control product.
The following description is made in connection with specific embodiments:
The experimental methods used in the following examples are conventional methods unless otherwise specified. Materials, reagents and the like used in the examples described below are commercially available and, unless otherwise indicated, the techniques not described in detail are carried out according to standard methods well known to those skilled in the art.
Example 1
Formulation of Lp-PLA2 antigen preservation solution scheme 1:
Taking a1 liter clean beaker, adding a magnetic stirrer, adding half volume of purified water, sequentially adding the following components, fully and uniformly mixing, testing the pH to 7.4+/-0.1, weighing to 1 liter, stirring and uniformly mixing, and filtering with a 0.45 mu m filter membrane.
Example 2
Formulation of Lp-PLA2 antigen preservative solution scheme 2:
Taking a1 liter clean beaker, adding a magnetic stirrer, adding half volume of purified water, sequentially adding the following components, fully and uniformly mixing, adjusting the pH to 7.5+/-0.1 by using hydrochloric acid, weighing to 1 liter, stirring and uniformly mixing, and filtering by using a 0.45 mu m filter membrane.
Material Component (A)
Trimethylolaminomethane 12.1g
Magnesium sulfate 10g
Lauryl alcohol ether potassium phosphate 0.5g
Tween-20 1g
Trehalose 50g
Bovine serum albumin 0.1g
Sodium azide 0.9g
Example 3
Formulation of Lp-PLA2 antigen-preserving fluid scheme 3:
Taking a1 liter clean beaker, adding a magnetic stirrer, adding half volume of purified water, sequentially adding the following components, fully and uniformly mixing, adjusting the pH to 7.5+/-0.1 by using hydrochloric acid, weighing to 1 liter, stirring and uniformly mixing, and filtering by using a 0.45 mu m filter membrane.
Example 4
Formulation of Lp-PLA2 antigen-preserving fluid scheme 4:
Taking a1 liter clean beaker, adding a magnetic stirrer, adding half volume of purified water, sequentially adding the following components, fully and uniformly mixing, adjusting the pH to 7.5+/-0.1 by using hydrochloric acid, weighing to 1 liter, stirring and uniformly mixing, and filtering by using a 0.45 mu m filter membrane.
Material Component (A)
Trimethylolaminomethane 12.1g
Sodium chloride 10g
Isooctyl alcohol polyoxyethylene ether phosphate 0.4g
Polyethylene glycol monolauryl ether 0.5g
Trehalose 100g
Polyvinylpyrrolidone K30 10g
Sodium azide 0.9g
Comparative example 1
The formulation was prepared as in example 1, except that potassium laureth phosphate was not added, and the other components were the same as those added in example 1.
The stock solutions prepared in examples 1-4 and comparative example 1 above diluted the Lp-PLA2 antigen to final concentrations of 100ng/mL and 400ng/mL, respectively, and were formulated into quality control 1 (100 ng/mL) and quality control 2 (400 ng/mL), and after mixing, were stored at 2-8deg.C. The Lp-PLA2 antigen is a recombinant antigen produced by Shenzhen Shangtai bioengineering Co.
The stability of the quality control 1 and the quality control 2 at different temperatures is tested respectively, and the specific experimental method is as follows:
Accelerated stability at 37 ℃): samples prepared in examples 1-3 and comparative example 1 were taken, each divided into 5 parts, placed at 37 ℃, and after taking out one of the samples at room temperature for equilibration on days 0, 1,3, 5, and 7, the samples were tested using the Lp-PLA2 (latex immunonephelometry) assay kit from Shenzhen Biotechnology Co., ltd, the test instrument was Beckmann AU680 Biochemical analyzer, and the average and relative deviation of all the test results were calculated, as shown in the following table:
From the above table, the deviation between the concentrations of the quality control products prepared by the diluents prepared in examples 1-4 on days 1, 3, 5 and 7 and the concentration on day 0 after the quality control products are placed at 37 ℃ is small, which indicates that the quality control products prepared in examples 1-4 are hardly degraded in 7 days or 7 days at 37 ℃, and have good stability; the deviation of the concentrations of the comparative example 1, 3, 5 and 7 days after the comparative example 1 without adding the potassium laureth phosphate and the concentration of the comparative example 0 is larger and larger, which shows that the longer the comparative example 1 is placed at 37 ℃, the more Lp-PLA2 is degraded, and the thinner of the examples 1-4 has better functions of protecting the Lp-PLA2 and preventing the degradation.
Room temperature bottle opening stability: samples prepared in examples 1-3 and comparative example 1 were taken, each divided into 4 parts, placed at room temperature, and after taking out one of the samples at room temperature for balancing at 0, 6, 12, 24 and 48 hours, the samples were tested with the Lp-PLA2 (latex immunonephelometry) assay kit of Shenzhen Shang Tai bioengineering Co., ltd, the test instrument was Beckmann AU680 Biochemical analyzer, and the average and relative deviation of all the test results were calculated, as shown in the following table:
From the above table, the deviation between the concentrations of the 6 th, 12 th, 24 th and 48 th hours and the concentration of the 0 th hour after the quality control products prepared by using the diluents prepared in the examples 1-4 are placed at room temperature is small, which indicates that the quality control products prepared in the examples 1-4 are hardly degraded in 48 hours or 48 hours at room temperature, and have better stability; the concentration of the quality control product prepared by the diluent prepared in the comparative example 1 without adding the laureth potassium phosphate deviates more and more from the concentration of the product prepared in the comparative example 1 in the 6 th, 12 th, 24 th and 48 th hours after being placed at room temperature, which shows that the longer the quality control product prepared in the comparative example 1 is placed at room temperature, the more Lp-PLA2 is degraded, and the better the effect of protecting the Lp-PLA2 and preventing the degradation of the diluent prepared in the examples 1 to 4 is achieved.
2-8Deg.C correction stability: samples prepared in examples 1-3 and comparative example 1 were taken, each divided into 5 parts, placed at 2-8deg.C, and after taking out one of the samples at 0, 4, 8, 12, 18 months, respectively, and balancing at room temperature, were tested with the Lp-PLA2 (latex immunonephelometry) assay kit of Shenzhen Shangtai bioengineering Co., ltd, the test instrument was Beckmann AU680 Biochemical analyzer, and the mean and relative deviation of all test results were calculated, with the results shown in the following Table:
From the above table, the deviation between the concentrations of 4 th, 8 th, 12 th and 18 th months and the concentration of 0 th month after the quality control product prepared by using the diluents prepared in the examples 1-4 is placed at 2-8 ℃, which shows that the quality control product prepared in the examples 1-4 is hardly degraded in 18 months or 18 months at 2-8 ℃, and has better stability; the deviation of the concentrations of 4, 8, 12 and 18 months and the concentration of 0 month after the quality control product prepared by the diluent prepared in the comparative example 1 without adding the laureth potassium phosphate is placed at 2-8 ℃ is larger and larger, which shows that the longer the quality control product prepared in the comparative example 1 is placed at 2-8 ℃, the more Lp-PLA2 is degraded, and the diluent prepared in the examples 1-4 has better functions of protecting the Lp-PLA2 and preventing the degradation.
The above description is only of the preferred embodiments of the present invention and is not intended to limit the invention, but any modifications, equivalents, improvements, etc. within the principles of the present invention should be included in the scope of the present invention.

Claims (9)

1. An Lp-PLA2 antigen preservation solution is characterized by comprising a buffer agent, inorganic salt, phosphate surfactant, nonionic surfactant, stabilizer and preservative;
Wherein the phosphate surfactant is one or salts of alkyl phosphate, aryl phosphate, fatty alcohol polyoxyethylene ether phosphate, alkylphenol polyoxyethylene ether phosphate, alkyl alcohol amide phosphate, imidazoline phosphate and high polymer polyphosphate; the structure of the phosphate surfactant is that Wherein R 1、R2 and R 3 are identical or different hydrophobic groups.
2. The Lp-PLA2 antigen-preserving fluid of claim 1, comprising 10-200mM buffer, 5-20g/L inorganic salt, 0.01-5g/L phosphate surfactant, 0.1-10g/L nonionic surfactant, 0.5-100g/L stabilizer, and 0.5-2g/L preservative.
3. The Lp-PLA2 antigen-preserving solution of claim 1, wherein the buffer is any one of phosphate buffer, tris-HCl buffer, good's buffer, citrate buffer, barbital buffer, and borate buffer, and the pH of the buffer is 6.0-8.5.
4. The Lp-PLA2 antigen-preserving fluid of claim 1, wherein the inorganic salt is any one of sodium chloride, potassium chloride, magnesium chloride, sodium sulfate, and magnesium sulfate.
5. The Lp-PLA2 antigen-preserving fluid of claim 1, wherein the phosphate surfactant is comprised of a hydrophilic moiety and a hydrophobic moiety, the hydrophobic moiety being an alkyl group or a fatty acid group, the hydrophilic moiety being a phosphate.
6. The Lp-PLA2 antigen-preserving fluid of claim 1, wherein the nonionic surfactant is any one or more of a polyol polyoxyethylene ether fatty acid ester, an alkylphenol polyoxyethylene ether, an octylphenyl polyoxyethylene ether, and a polysorbate, and has a hydrophilic-lipophilic balance of 13-18.
7. The Lp-PLA2 antigen-preserving fluid of claim 1, wherein the stabilizer is any one or more of a polyol, a saccharide, a macromolecular inert protein, and a high molecular polymer.
8. The Lp-PLA2 antigen-preserving fluid of claim 7, wherein the polyol is ethylene glycol, glycerol, mannitol, or sorbitol, the saccharide is sucrose, trehalose, or chitosan, the macromolecular inert protein is bovine serum albumin, human serum albumin, casein, or gelatin, and the high molecular polymer is polyvinylpyrrolidone.
9. The Lp-PLA2 antigen-preserving fluid of claim 1, wherein the preservative is any one or more of sodium azide, proClin300,300, gentamicin, parabens, and isothiazolinones.
CN202311215216.5A 2023-09-19 2023-09-19 Lp-PLA2 antigen preservation solution Active CN117517656B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311215216.5A CN117517656B (en) 2023-09-19 2023-09-19 Lp-PLA2 antigen preservation solution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311215216.5A CN117517656B (en) 2023-09-19 2023-09-19 Lp-PLA2 antigen preservation solution

Publications (2)

Publication Number Publication Date
CN117517656A CN117517656A (en) 2024-02-06
CN117517656B true CN117517656B (en) 2024-09-17

Family

ID=89755670

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311215216.5A Active CN117517656B (en) 2023-09-19 2023-09-19 Lp-PLA2 antigen preservation solution

Country Status (1)

Country Link
CN (1) CN117517656B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111398586A (en) * 2020-03-07 2020-07-10 苏州德沃生物技术有限公司 Single reagent L P-P L A2 latex enhanced immunoturbidimetry assay kit
CN112763731A (en) * 2020-12-29 2021-05-07 广州市伊川生物科技有限公司 Lipoprotein (a) determination kit and detection method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566408B1 (en) * 2000-08-01 2003-05-20 Rhodia, Inc. Aqueous surfactant compositions of monoalkyl phosphate ester salts and amphoteric surfactants
CA2704729C (en) * 2007-08-28 2020-06-23 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111398586A (en) * 2020-03-07 2020-07-10 苏州德沃生物技术有限公司 Single reagent L P-P L A2 latex enhanced immunoturbidimetry assay kit
CN112763731A (en) * 2020-12-29 2021-05-07 广州市伊川生物科技有限公司 Lipoprotein (a) determination kit and detection method thereof

Also Published As

Publication number Publication date
CN117517656A (en) 2024-02-06

Similar Documents

Publication Publication Date Title
US7803911B2 (en) Dried blood factor composition comprising trehalose
US4299726A (en) Process for preparing whole blood reference controls having long term stability, preconditioning diluent and media therefor
KR100196107B1 (en) Prothrombin Time Reagent Based on Tissue Factor and Its Manufacturing Method
US20070167368A1 (en) Dried blood factor composition comprising trehalose
EP1975622B1 (en) Method for stabilizing tissue factor
EP0123291A2 (en) Method for stabilizing interferon
Schechter et al. Erythrocyte spectrin. Purification in deoxycholate and preliminary characterization
CN117517656B (en) Lp-PLA2 antigen preservation solution
EP1418229B1 (en) Method of stabilizing alkaline phosphatase
Gratecos et al. Plasma membranes from rat intestinal epithelial cells at different stages of maturation. I. Preparation and characterization of plasma membrane subfractions originating from crypt cells and from villous cells
JP2010154851A (en) Protein extraction agent
JP5119545B2 (en) Method for stabilizing protein in liquid composition containing protein
JP2817606B2 (en) Method for stabilizing endotoxin in aqueous solution
JP3696267B2 (en) Method for stabilizing bioactive protein
Mukaiyama et al. Dextran sodium sulfate enhances secretion of recombinant human transferrin in Schizosaccharomyces pombe
Post et al. Sarcolemmal disruption during the calcium paradox
ADACHI et al. Superoxide dismutase levels following liver and kidney intoxication
US5378609A (en) Lipase single reagent system
Wieslander et al. Fractionation of membranes from Acholeplasma laidlawii A on the basis of their surface properties by partition in two-polymer aqueous phase systems
CA2287129C (en) Stabilization of biological fluids by addition of sterol esters
ES3014597T3 (en) Compositions, methods, and kits for detection of lipolytic activity
EP0399379B1 (en) A lipase reagent system
US5770451A (en) Liquid lipoprotein control
JPH10282105A (en) Manufacture of calibrator for measuring serum amyloid a
JPH09509064A (en) Isoenzyme calibrator / control products

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant